braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - agentes antineoplásicos - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
braftovi cápsulas 50 mg (encorafenib)
pfizer chile s.a. - encorafenib - sin formulas
braftovi cápsulas 75 mg (encorafenib)
pfizer chile s.a. - encorafenib - sin formulas
mektovi
pierre fabre medicament - binimetinib - melanoma - agentes antineoplásicos - binimetinib en combinación con encorafenib está indicado para el tratamiento de pacientes adultos con irresecables o melanoma metastásico con gen braf v600 mutation.
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
braftovi 50 mg
pfizer inc estados unidos - cada cápsula contiene: encorafenib (a)? 50.000mg - capsulas - cada cápsula contiene: encorafenib (a)? 50.000mg
braftovi 75 mg
pfizer inc estados unidos - cada cápsula dura contiene: encorafenib (a)? 75.000mg - capsula dura - cada cápsula dura contiene: encorafenib (a)? 75.000mg
mektovi comprimidos recubiertos 15 mg (binimetinib)
pfizer chile s.a. - binimetinib - sin formulas
paxlovid comprimidos recubiertos
pfizer chile s.a. - nirmatrelvir; ritonavir - sin formulas
braftovi 75 mg cápsula
pfizer - cápsula - encorafenib 75 mg cápsula